Gradient (catheter for the treatment of pulmonary hypertension)

2023: Product Announcement

On September 7, 2023, Gradient Denervation Technologies announced the development of a catheter to treat pulmonary hypertension, a disease that can be fatal.

The named ailment manifests itself in an increase in pressure in the pulmonary circulation. This leads to right ventricular overload and right ventricular insufficiency. The main symptoms of the disease are fatigue, shortness of breath during physical exertion, chest discomfort and fainting conditions. In severe cases, pulmonary hypertension turns into the death of the patient.

Pulmonary hypertension manifests in increased pressure in the pulmonary circulation

Gradient technology provides for a decrease in sympathetic activity in the pulmonary vasculature. Catheter therapy targets people with group 2 pulmonary hypertension, which includes patients with heart failure and high pulmonary vascular resistance. Up to 50% of heart failure patients suffer from this debilitating condition, but there are no approved treatments as of September 2023. The minimally invasive approach developed by Gradient specialists is based on the use of ultrasound energy to perform a denervation procedure.

In addition, Gradient announced a Series A funding round, during which €14 million was raised for development. This investment program was led by the firm Asabys Partners through its new fund Sabadell Asabys II. In addition, Thuja Capital and Sofinnova Partners participated in the round.

Gradient technology could potentially be a first-in-class treatment for patients suffering from heart failure and elevated pulmonary pressure. The company is ready to prove the effectiveness of its technology in a clinical setting, and we look forward to joining this project, "said Sylvain Sachot of Asabys Partners.[1]

Notes